GenVivo, Inc.
Robert G. Johnson, MD, PhD has a vast amount of experience in the biopharmaceutical industry. Currently serving as the COO at GenVivo, Inc., Robert also holds various leadership positions at organizations such as the University of Pennsylvania Perelman School of Medicine and the Hope Funds for Cancer Research. Additionally, Robert G. is the principal at Aeolian Biomed, providing consulting services for the industry. With a background in medicine and biophysics, Robert has held top executive positions at companies like Epeius Biotechnologies Corp., Kosan Biosciences, Chiron Corporation, and Merck.
This person is not in any teams
GenVivo, Inc.
GenVivo was founded on the idea that we can effectively treat cancer patients with the latest gene delivery technologies. We are committed to enhancing the overall patient treatment experience. We deliver innovative drugs to empower the patient’s own immune system to mount a targeted attack against cancer. These therapies are off-the-shelf and come without the cost and time delays associated with personalized cancer vaccines. We are dedicated to providing accessible and efficient solutions that redefine the landscape of cancer treatment.